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CHAPTER 1: INTRODUCTION
A. Folate Overview and Metabolism
The B-vitamin folate has long been known to play an important role in human
health. Impaired folate metabolism is associated with several pathologies and
developmental abnormalities, including neural tube defects (NTD) [1, 2], cardiovascular
disease (CVD) [3, 4], and cancer [5-9]. Folate metabolism can be disrupted by B-vitamin
deficiencies, folate antagonist medications, and penetrant genetic mutations and
polymorphisms [10-13]. However, the risk associated with these disruptions, as well as
interactions with other environmental risk factors, have yet to be fully elucidated.
Folic acid is the synthetic monoglutamated form of folate found only in fortified foods
and supplements, whereas natural food folates are a mixture of the reduced forms of the
vitamin with a variable number of glutamate residues. Natural folates in foods are labile
and prone to oxidative damage when compared to synthetic folic acid, which is
considerably more stable and has significantly higher bioavailability. Mixed dietary intake
of fortified and natural food sources of folate are regularly reported in dietary folate
equivalents (DFE) to account for differences in the absorption of naturally occurring food
folate and the more bioavailable synthetic folic acid.
Folate metabolism involves the reduction of folic acid by dihydrofolate reductase to
form tetrahydrofolate (THF), the active form of folate and cofactor in single-carbon
enzymatic reactions. The ability of folate cofactors to accept or donate one-carbon units
at the N-5 and/or N-10 positions without changing their nature is essential for several
important

biochemical

processes

including

purine

and

thymidylate

remethylation, and S-adenosyl methionine (SAM) formation. (Figure 1.1).

synthesis,
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Figure 1.1 Overview of Folate Metabolism [14]. THF derived methyl groups are
transferred in the synthesis of dTMP, purines, methionine and subsequently SAM.

Figure 1.2 De Novo Synthesis of Purines [15]. Formyl group is transferred to form
purine ring at step 3 via GAR (glycinamide ribonucleotide) and step 9 via AICAR (5aminoimidazole-4-carboxamide ribonucleotide) to form IMP (inosine monophosphate),
the adenine and guanine nucleotide precursor.
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Figure 1.3 Folate dependent conversion of dUMP to dTMP [16]. Thymidylate synthase
catalyzes the methyl transfer from 5,10, methylene THF to dTMP.

De novo synthesis of the adenine and guanine require two folate-dependent
transformylases; GAR and AICAR, which facilitate the transfer of the formyl group from
10-formyl THF to form the purine ring at C-2 and C-8 (Figure 1.2). Folate is also required
as a coenzyme for the conversion of deoxyuridine monophosphate (dUMP) to
deoxythymidine monophosphate (dTMP) in a reaction catalyzed by thymidylate synthase
(TS) (Figure 1.3). Due to significantly increased proliferation in transformed cells,
antifolate drugs that limit the source of one-carbon moieties, specifically, 10-formyl-THF
in de novo purine biosynthesis and 5,10-methylene-THF in dUMP to dTMP conversion
are effective chemotherapeutics since they reduce the nucleotide pool available for
replication.
The remethylation of homocysteine to methionine is catalyzed by methionine synthase
(MS) in a 5-methyl-THF, zinc and B12-dependent reaction (Figure 1.1). Disruptions in
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methionine metabolism not only lead to accumulation of homocysteine, which is a risk
factor for CVD and possibly Alzheimer’s disease, but may also diminish the availability of
other folate cofactors for nucleotide synthesis due to a “5-methyl-THF trap [17].”
Additionally, most cellular processes in which a compound acquires a methyl group use
SAM as the methyl donor. The labile methyl group that enables SAM to serve that function
is derived from its precursor, methionine, which in turn obtains that moiety from 5methylTHF. Due to the role of SAM-dependent methylation in epigenetic regulation,
inadequate levels of SAM have been linked to abnormalities in DNA methylation patterns.
B. Folate Status and Pathologies of Deficiency in Humans
In the United States, the current RDA for folate in men and non-pregnant women
over 14 years is 400 µg/d DFE. This level is intended to meet the nutrient requirement for
approximately 98% of the population, and is based on the average serum RBC folate, an
index of tissue stores, and long-term status [18, 19]. Folate requirements are higher
during life-stages in which there is increased cell division, such as during fetal
development and lactation, during which the RDA increases to 600 ug/d and 500 ug/d,
respectively.
Although most people consume adequate amounts of folate, due in part to the US
fortification program discussed below, the National Health and Nutrition Examination
Survey (NHANES) reports that certain groups, including women of childbearing age and
non-Hispanic black women, have higher levels of insufficient folate intakes. Even when
intakes of folic acid from dietary supplements are included, 19% of female adolescents
aged 14 to 18 years and 17% of women aged 19 to 30 years do not meet the estimated
average requirement [20]. Similarly, 23% of non-Hispanic black women have inadequate
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total intakes, compared with 13% of non-Hispanic white women. In addition, certain
populations are known to be at elevated risk for clinical folate deficiency due to inadequate
absorption or impaired metabolism, this includes chronic alcohol abusers, patients with
malabsorptive disorders and sickle cell disease, those requiring renal dialysis, and those
on clinical antifolate therapy for treatment of cancer or autoimmune disorders.
Folate is required for adequate growth and repair by virtue of its functions in
nucleotide biosynthesis, which impacts many different systems, some of which are
described below. Megaloblastic anemia resulting from folate deficiency, which can occur
at serum folate levels between 2-6 ng/mL, is characterized by hypercellular bone marrow
with large erythroblasts and uncondensed chromatin, leading to elevated mean cell
volume. Additionally, there is increased cell death of these abnormal megaloblasts prior
to maturation, leading to pancytopenia and anemia. These features have been directly
attributed to impaired DNA synthesis and methylation in the folate deficient state in
hematopoietic cells. In vitro studies of folate deficiency in erythroblasts indicate apoptosis
occurs in S phase suggesting a deficiency of available nucleotides [21]. The trigger for
bone marrow apoptosis is unknown, although DNA damage from double strand breaks
(DSB) in folate deficiency may play a role [22]. Nonetheless, it is apparent that purine and
thymidine synthesis from one-carbon metabolism is important in preventing megaloblastic
cell death.
Folate status has also been linked to vascular and neurological disease in
epidemiological studies [23-26]. This link is supported by multiple plausible mechanisms
including hyperhomocysteinemia from incomplete B12-dependent remethylation of
homocysteine to methionine, impaired DNA replication leading to damage of the
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endothelium [27], decreased SAM production resulting in hypomethylation, as well as an
age related decline in THF transport across the blood-brain barrier [28, 29]. Though, the
role of folate in the pathogenesis of vascular and neurological disease remains
controversial, and clinical trials suggest that vitamin supplementation appears beneficial
only in those with baseline intake well below the EAR [30, 31].
The most severe manifestation of disrupted folate metabolism is the occurrence of
birth defects that interfere with the development and closure of the neural tube. The
prevalence of NTDs in the US is approximately 0.8 per 1,000 births [32]. The association
between maternal folate status and the risk of NTDs is not fully understood; however,
compelling evidence from clinical trials demonstrated that maternal intake of folic acid
significantly reduced the occurrence and recurrence of NTDs by 44-71% [32-35].
In 1998, due to mounting evidence of the protective effect of maternal folic acid
supplementation in the periconceptional period, the US FDA required cereal and grain
products to be folic acid fortified. Currently, grain products are fortified at 140 µg of folic
acid per 100g of flour. Several studies from population-based state surveillance systems
have reported a 19-32% reduction in the overall birth prevalence rate of NTDs [31, 32] as
a result of the fortification program. An additional outcome of fortification was an increase
in the overall folic acid intake for all US populations. The median blood folate
concentration in the US population increased approximately 3-fold from 5.5 ng/mL prefortification, to 14.1 ng/mL in the subsequent 1999-2000 NHANES survey period.
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C. Folate and Carcinogenesis
Folate and Cancer Risk
Folate metabolism is crucial for many important biochemical processes that support
cell proliferation and epigenetic regulation. Unsurprisingly, insufficient folate availability
has been causally linked with many types of cancer. Over the past 40 years a large body
of epidemiological research has suggested that raised intakes or concentrations of folate
protect against several major human malignancies including colorectal, pancreas,
prostate, breast, cervical, and hematopoietic cancers [36, 37]. However, the use of folate
antagonists, starting in the 1950’s, as effective chemotherapy agents demonstrate the
duality of intracellular folate status, and recent studies have highlighted the association
between elevated folate levels and an increased risk of some cancers [38]. These studies
suggest a complex interplay between folate intake, existing genetic polymorphisms in
folate metabolism, and the stage and site of cell transformation. This is especially relevant
in relation to existing fortification programs where the daily upper limit (UL) of folate in
DFE can easily be surpassed with supplementation. [39-41]. Although the specific
molecular basis for the association between folate and cancer is unclear, there are two
highly

researched

pathways

that

have

been

hypothesized;

global

genomic

hypomethylation, and dNTP deficiency leading to increased uracil misincorporation into
DNA. The rationale for these two carcinogenic pathways is outlined in Figure 1.4.
Inadequate levels of one-carbon nutrients such as folate are linked with DNA
hypomethylation through decreased SAM production. Aberrations of DNA methylation are
common in cancer and are hypothesized to be involved in its development. However, a
review completed by Crider et. al. in 2012 indicates that the majority of studies on folate
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and global hypomethylation have only examined a limited number of genetic loci and/or
a small number of samples and to-date, and the available research does not support a
linear relationship or dose response between folic acid and global or site-specific DNA
methylation level [8].

Figure 1.4 Potential Mechanisms by which Folate Modifies Cancer Risk [42].

Uracil Misincorporation
A crucial step in the biosynthesis of deoxythymidine triphosphate (dTTP) is the
methylation of dUMP to dTMP, which is catalyzed by TS in a folate-dependent reaction
(Figure 1.3). Perturbations in this cycle can have a profound effect on the cellular
dUTP/dTTP ratio [43]. During the G1 to the S phase of the cell cycle, TS concentration is
increased at multiple levels of regulation to ensure adequate levels of dTTP for
incorporation into replicating DNA. However, a reduction of THF precursors, mainly
through insufficient folate availability, concomitantly reduces dTTP synthesis and
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increases dUTP accumulation. Since replicative DNA polymerases have similar affinity
for both deoxynucleotides, incorporation of dUTP is largely dependent on the relative
cellular pool sizes of dTTP and dUTP [44, 45]. During S phase, detection of
misincorporated uracil at the replication fork will signal for repair, primarily by the base
excision repair (BER) pathway. If the uracil lesions are extensive, the cell cycle may be
arrested until the uracil can be processed by BER, or apoptosis may ultimately occur.
D. Base Excision Repair of Uracil Lesions
Excision of misincorporated uracil from the genome is completed by the BER
pathway (Figure 1.5). This process is initiated by damage-specific glycosylase cleavage
of the N-glycosylic bond to excise the uracil base. In nuclear DNA, UNG2 is the uracil
DNA glycosylase predominately responsible for this step [46, 47]. Uracil is quickly
identified and removed from post-replicative DNA via the long patch process involving
PCNA. However, genomic uracil that escapes the replication fork is repaired primarily via
the short-patch route. Of the three additional uracil DNA glycosylases present in humans,
only SMUG1 has a role in excising uracil from single strand DNA (ssDNA), though this
may be limited to excision of deaminated cytosines [48]. Luhnsdorf et. al. found that
processing of U:A mismatches resulting from uracil misincorporation may be different
from that of U:G pairs resulting from cytosine deamination [49]. Likewise, TDG prefers
U:G mismatch substrates, exclusively in double-stranded DNA (dsDNA), while MBD4
seems to function at specific loci in double-stranded DNA [50].
After UNG2 excisional action in BER, the resulting abasic (AP) site is cleaved by
the endonuclease, APE1. In dsDNA BER then typically proceeds via the short patch route
with excision of the 5’-deoxyribose-5-phosphate residue (5’dRP) and insertion of the
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appropriate base paired nucleotide to the 3’ end of the gap through the coordinated action
of polymerase β (POLβ). A DNA ligase then functions to seal the remaining nick.

Figure 1.5 Outline of the Base Excision Repair Pathway [46]. The short-patch
pathway, shown on the left is responsible for repair of genomic uracil. On the right, the
long-patch pathway processes uracil at the replication fork. Both processes are initiated
primarily by the Uracil DNA glycosylase UNG.
Incorporation of dUMP through one round of replication in dsDNA containing 30%
thymine has been estimated in the range of 2-10 x 107 based on the dUTP/dTTP ratio
observed in human tumor cell lines. However, the genomic level of uracil is 4-5-fold lower,
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suggesting that a large number of these uracils are rapidly removed by post-replicative
BER [46, 47, 51]. The consequences of misincorporated dUMP that persists in DNA are
still relatively unknown, though there is evidence that it may have deleterious effects on
gene expression, and genomic stability through incomplete repair of AP sites or errors in
gap-filling in the BER process [52, 53].
Effect of Folate Deficiency on BER
While folate deficiency is known to increase DNA strand breaks, somatic
mutations, and chromosomal aberrations, the mutagenic response to DNA-damaging
agents such as ethyl nitrosourea, ethyl methanesulfonate, and hydrogen peroxide is also
greater when folate is deficient. This phenotypic response closely resembles the effects
of inadequate or fragmented DNA repair activity. These findings point to a folate
deficiency-induced inability to process the types of DNA damage repaired by the BER
pathway. In support of this hypothesis, Unnikrishnan et. al. found that folate depletion
prevents BER induction in murine liver tissue by blocking a region in the CRE element of
POLβ, the rate limiting enzyme in BER [54]. Since BER is a damage-inducible pathway,
this study suggests that folate depletion may prevent this upregulation at the level of
transcription. Given the role of folate in SAM production, the methylation pattern of the
CpG-rich regions sites was investigated, but no methylation differences in the POLβ
promoter between the folate adequate and folate deficient tissues were found, making
hypomethylation an unlikely contributor. Since DNA polymerases require sufficient dNTP
levels for optimal functioning, it is possible that folate deficiency, due to its role in purine
synthesis and dTTP formation, may contribute to the regulatory effect on POLβ through
reduced dNTP availability.
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UNG2-mediated induction of BER begins a series of enzymatic reactions that
induces a transient break in the phosphodiester backbone that will persist until the
appropriate nucleotide is inserted by POLβ. Figure 1.6 demonstrates how the removal of
uracil by UNG2 and APE1 creates a 3’-OH lesion that persists until POLβ is available to
insert a new nucleotide, and the repair can be completed. Accumulation of repair
intermediates due to insufficient inducibility of POLβ in folate deficiency are a likely source
of the strand breaks and genomic instability generally seen in this condition.
Concerningly, there is evidence that UNG activity is actually induced in folate deficient
liver tissue, without a corresponding upregulation of subsequent BER enzymes [55].
Without a sufficient POLβ, increased BER initiation by UNG2 may increase the amount
of unprocessed repair intermediates significantly. Thus, accumulation of DNA singlestrand breaks associated with folate deficiency may be due to an imbalance of repair
proteins. Single strand breaks due to attempted BER can be converted to a DSB if the
lesions are clustered in opposing strands in the DNA. DSBs, in which both strands of the
double helix are severed, is particularly hazardous to the cell because they can lead to
gene rearrangements. Therefore, folate deficiency may contribute to accumulation of
unstable repair intermediates, and consequent DSBs by two mechanisms: a) an
imbalance in dUMP:dTMP ratio resulting in increased uracil incorporation and stimulation
of BER through upregulation of the uracil DNA glycosylase, and b) by inhibiting the rate
limiting step in the repair process.
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Figure 1.6 Base Excision Repair Intermediate [56]. Following the action of a DNA
glycosylase, APE1 hydrolyzes the phosphate bond 5′ to the AP site and generates a
single strand break with a 3′-OH end group on one strand and a 5′ terminal 2′-deoxyribose
phosphate residue (5′-dRP) residue on the other strand.
E. Tissue Specific Inducibility of BER
Misincorporation of uracil as a result of folate deficiency has been reported in studies
in lymphocytes and it has become a de facto assumption that accumulation of uracil in
DNA occurs ubiquitously when folate is depleted [6, 57]. Subsequent reports of uracil
accumulation have involved manipulations including a knockdown model of Shmt [58],
Ung-null yeast [59], additional methyl depletion [60], aging [61], and methotrexate
exposure [62]. However, using an uracil DNA glycosylase-coupled aldehydic slot blot
assay developed by Nakamura et. al. [63] and adapted by Cabelof et. al. [64], unpublished
results from our lab indicate that there is no accumulation of uracil in liver tissue from
animals depleted of folate. Though there is a reported increase in uracil excision activity
in these animals [55]. In support of this finding, no uracil accumulation was reported in rat
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colonocytes [57], and in mouse brain, folate deficiency also had no impact on uracil
accumulation [65]. To evaluate whether different cell types have a distinct response to
folate deficiency, our lab cultured transformed liver cells derived from BALB/c mice
(BNL.C2) and transformed mouse embryonic fibroblasts, Tag 92 (MEF) cells in folate-free
media in a yet-to-be published study. The BNL.C2 cells exhibited inducibility of UDG
similar to previous findings of a clastogenic phenotype of folate deficiency in murine liver
tissue [55], but no accumulation of uracil. However, in MEFs we found a 40% increase in
the accumulation of uracil in genomic DNA but observed no upregulation of UNG. This is
despite equivalent responses at the level of folate uptake, retention and metabolism.
These results seem to correspond to a tissue specific UNG response to folate deficiency
whereas fibroblasts lack inducibility of UNG, resulting in more accumulation of uracil in
the DNA, yet liver cells continue to upregulate UNG in folate deficient states. In the latter
scenario, these cells types are subject to the mutagenic repair intermediates associated
with BER imbalance in folate deficiency. In the case of phenotypic uracil accumulation,
as discussed, misincorporated dUMP may increase risk of genomic instability. More
pertinent however is uracil that enters the DNA by deamination of cytosine, which will
result in a U:G mismatch that, if left unprocessed, can produce a highly carcinogenic C to
T transition mutation as shown in Figure 1.7.
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Figure 1.7 Transition Mutation Resulting from Cytosine Deamination [66]. Loss of
ammonia group during hydrolytic cytosine deamination resulting in uracil. If uracil strand
is replicated, it will result in U:A and eventually T:A transition mutation in place of C:G
pair.

F. AID and the Adaptive Immune Response
In addition to misincorporated dUMP and spontaneous deamination of DNA
cytosine, a third source of uracil in DNA has been identified as an essential intermediate
in both adaptive and innate immunity. The targeted action of activation-induced cytidine
deaminase (AID) introduces uracils into the B-cell genome, primarily in the
immunoglobulin (Ig) loci in order to initiate the process of efficient antibody development
[67]. Likewise, APOBEC A3 enzymes, which are highly expressed in immune cells,
restrict viral replication by deaminating cytosines. This action results in direct mutation
and degradation of the viral DNA by UNG2 (or SMUG1) and APE. The deamination of
cytosine by AID and APOBEC enzymes has attracted interest not only due to their
importation role in the adaptive and innate immune systems, respectively, but also due to
their suspected role in human oncogenesis. Sequencing of human cancer genomes has
identified mutational signatures in many cancer types attributed to the AID/APOBEC
family of deaminases, indicating a significant contribution by genomic uracil in the
mutations found in many cancer types [68].
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Target action in IG genes
Activated B cells have developed complex mechanisms to combat pathogenic
bacteria, viruses, and parasites. Somatic hypermutation (SHM) and class switch
recombination (CSR) are antigen-dependent diversification processes which depend on
AID and subsequent error-prone trans-lesion (TLS) repair to produce high affinity
antibodies. These molecules can recognize and bind to any foreign molecules, known as
antigens, and thereby neutralize potential disease-causing agents. In both of these
processes, uracil is introduced into the B-cell genome at the immunoglobulin (Ig) loci by
the canonical action of AID [67]. Notably, UNG2 is the glycosylase used almost
exclusively during repair of AID-induced lesions in both SHM and CSR.
Millions of B lymphocytes are generated in the bone marrow every day as well as
in the liver during fetal development. Each of these cells express a unique variant of
membrane-bound Ig antibody proteins thanks to V(D)J rearrangement of the somatic Ig
genes. Antibody molecules consist of a constant effector region, and a variable antigenbinding region. In naive B lymphocytes the variable region is acted on by the enzymes
recombinase activating gene 1 & 2 to induce double strand breaks (DSB). These DSBs
stimulate gene rearrangement by non-homologous end joining in the V, D, and J domains
of the Ig gene. This process is non-antigen dependent and creates an immense diversity
of B-cell receptors in these naive cells.
Once matured, B-cells are released into the blood and migrate to the secondary
lymphoid organs, primarily the spleen and lymph nodes. When antigens are presented by
dendritic cells, the activated B-cells form germinal centers where they undergo clonal
expansion, AID-dependent SHM and CSR, selection by affinity maturation, and
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differentiation into memory B cells or plasma cells. AID is highly expressed in activated
B-cells, prompting both SHM and CSR to take place in the germinal centers.
Somatic Hypermutation
During SHM, single nucleotide substitutions increase the diversity at the IgV loci
by error prone repair of AID-induced uracils in the DNA. There are three main pathways
by which mutations are generated in SHM. The first is by direct replication of AID
generated uracil. Identical to the process outlined in Figure 1.7, uracil is then read as
deoxythymidine by replicative DNA polymerases, resulting in a cytosine to thymine
transition mutation [67]. The second source of mutations involves the action of UNG2 to
excise uracil, leaving an abasic site. This site may be acted on by error-prone trans-lesion
TLS polymerases, resulting in a non-template addition of any base across from the AP
site. In the third pathway, U:G mismatches are acted on by a non-canonical MutSadependent mismatch repair (MMR) process, which may interact with BER to further
induce mutagenesis during antibody diversification [69].
Class Switch Recombination
In CSR, DSBs are initiated by AID activity within specific sequences known as
switch regions on the Ig gene. The molecular mechanisms that generate DSBs during
CSR are similar to SHM. The two main pathways for uracil processing in these switch
regions are both UNG2-dependent. The first pathway relies on the proximity of uracil
excisions followed by AP endonuclease (APE1) action to generate DSBs. In the second
pathway, UNG2/APE1 and components of the MMR pathway cooperate to produce
DSBs. A simplified overview of UNG2-initiated error-prone repair process utilized by SHM
and CSR is outlined in figure 1.8. The coordinated action of AID in SHM and CSR grants
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the B-cell pool the potential to generate an unlimited repertoire of highly specific
antibodies, with each cell expressing Ig on its surface with a unique antigen-binding
specificity.

Figure 1.8 Ig Diversification by CSR and SHM [70]. Simplified model of processing of
genomic uracil during Ig diversification in activated B-cells. UNG2 is the glycosylase that
processes AID-induced uracil at Ig switch (S) and variable (V) regions to promote CSR
and SHM.
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Non-target AID action
Although AID and APOBEC A3 DNA deaminases are required for both the first line
innate and second line adaptive immune systems to protect us from infection and disease,
the deaminating action of these enzymes in non-target sites can cause mutations that
may lead to cancer. Specifically, evidence has been growing in support of a
lymphomagenic effect of AID and other APOBEC enzymes action in mature B cells.
These actions may take place on the Ig loci, possibly as a result of dysregulated CSR or
SHM, as well as outside of the Ig gene, contributing to genome-wide mutations. Studies
in mice have indicated that the off-target action of AID contributes to somatic mutations,
DNA breaks, and chromosomal translocations [71]. Additionally, AID was shown to be
required for lymphomagenesis in mouse models of B-cell lymphoma driven by the ectopic
expression of oncogenes [72]. Interestingly, UNG-/- mice develop B-cell hyperplasia and
lymphomas at higher frequencies than normal mice, suggesting that B cell maturation in
the absence of UNG promotes oncogenic transformation.

20

CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS
Evidence suggests that in some tissues, such as fibroblasts, the initiation of the
BER pathway is disrupted when folate is depleted. In MEF cells, downregulation of UNG2
results in increased genomic uracil content (unpublished results). It has been established
that uracil accumulates in folate deficient lymphocytes, though enzymatic regulation of
BER in these cells has not been reported [73]. Since folate deficiency is known to increase
incorporation of dUMP into the genome in place of dTMP [6], insufficient UNG2 in this
condition would limit repair of these uracil lesions, possibly affecting gene expression at
the site of incorporation and reducing proliferation due to overwhelmed repair
requirements at the replication fork.
Decreased dNTP availability has been reported in folate deficient cells and thought
to be responsible for reduced replication, cell cycle arrest, and possibly decreased activity
of polymerases such as POLβ in some cell types [74]. Therefore, in addition to
overwhelmed repair requirements, nucleotide deficiency due to reduced folate availability
may also contribute to significantly increased cellular doubling time. This is particularly
relevant in highly proliferative B-lymphoblastoids which are sensitive to the effects of
nucleotide deficiency. In addition, UNG2 expression is cell cycle regulated, with the
highest mRNA levels just prior to and during S phase. As such, cell cycle interference
may contribute to a tissue specific effect in these conditions. Therefore, we hypothesized
that moderate folate deficiency would significantly reduce proliferation in Blymphoblastoids in vitro.
Finally, given the role of UNG2 in AID-initiated repair, and the possible
consequences of off-target AID action, we were interested as to whether folate deficiency
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may disrupt repair of uracils resulting from genomic cytosine deamination in the context
of adaptive immunity. Since BER is a damage-inducible pathway, UNG2 is known to be
tightly correlated with AID expression and activity [75]. In AID-expressing B-cells we
would expect to see an upregulation of BER through UNG2 and POLβ expression.
However, in folate deficiency we have evidence to suggest that UNG2 will be
downregulated in lymphoblast cells. Thus, we seek to establish the relationship between
AID expression and BER inducibility in folate deficient B-lymphoblastoids.
To investigate our hypothesis that tissue specific downregulation of BER in
folate deficient B-lymphoblastoids will result in a functional imbalance between
AID and uracil repair capacity, we tested the following Specific Aims:
Specific Aim 1: Confirm the effect of low folate media on intracellular folate
concentration, proliferation, and dNTP level in B-lymphoblastoid cells in vitro.
Specific Aim 2: Establish whether there is a tissue specific effect of folate deficiency on
BER inducibility of UNG2 and POLβ expression in B-lymphoblastoid cells.
Specific Aim 3: Determine if folate deficiency has an effect on the balance of UNG2
and AID expression in lymphoblastoid cells in vitro.
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CHAPTER 3: MATERIALS AND METHODS
A. Cell Culture and Proliferation Study
Transformed human lymphoblastoid cells were obtained from Coriell Cell Repositories
(Camden, NJ) and cultured in RPMI 1640 medium (Invitrogen) with standard folic acid
concentration of 12 nM, supplemented with 15% dialyzed fetal bovine serum (Invitrogen),
1% antibiotics (penicillin/streptavidin), 0.5% L-glutamine (Glibco), and 1% glutaMAX
(ThermoFisher). Folate deficiency was induced in experimental cells by culturing in folate
free RPMI 1640 medium and adding folic acid (Sigma) for a final concentration of 12 nM.
Every 3-4 days the cells were spun down, sampled for expression, folate concentration,
and proliferation analysis, and resuspended at 0.5 x 106 cells/ml in fresh medium plus
10% used medium. At days 3, 6, and 11 of culture, live cells were counted with a
hemocytometer, recorded per 8 ml, and the doubling time was calculated.
B. Lactobacillus casei Folate Assay Optimization
Depletion of folate concentration in the experimental lymphoblastoid cells was
confirmed using the microbiological method as described by Horne and Patterson, and
optimized for measuring relative folate concentrations of cultured cells with the methods
as follows. Folate standard and depleted lymphoblastoid cells were harvested at days 6,
10, 14, 18 and 21 at a standardized concentration of 106 cells/ml, washed in PBS, and
stored at -80°C. Within 72 hours prior to assay, folinic acid standard solution along with
50 ml of homogenization buffer and 30 ml of extraction buffer was prepared and stored
at 4°C however, beta-mercaptoethanol was withheld from solutions until immediately prior
to sample preparation. A serial dilution of 6 mM folinic acid calcium salt solution (Sigma)
was prepared to a final solution with a concentration of 2 fmol/ul folinic acid. Light
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exposure to dilution solutions was minimized with a low lighting and aluminum foil
wrapped tubes to minimize vitamin degradation. Homogenization buffer (0.25 M sucrose,
10 mM HEPES, 10 mM ascorbic acid, 10 mM beta-mercaptoethanol) was prepared with
the first three components plus approximately 30ml diH2O and heated to dissolve
completely. Upon return to ambient temperature, 5 M NaOH was added in 500 ul
increments until pH reached 7.4 as measured by calibrated benchtop pH meter.
Additional diH2O was added to bring solution to 50ml. Extraction Buffer (10% w/v
ascorbic acid, 0.25 M HEPES, 0.25 M CHES, 1 M beta-mercatoethanol) was prepared
with the first three components plus approximately 10 ml ddH2O, pH was brought to 7.85
using procedure described above, and diH2O was added to bring final volume to 30ml.
Bacterial inoculum was prepared by applying a sterile loop to a previously prepared
L. casei glycerol stock, (one vial lyophilized Lactobacillus rhamnosis (ATCC 7469), single
strength folic acid casei medium-prepared as described in the package insert, glycerol),
subcultured in 5ml single strength medium, and grown for at least 18 hours at 37°C. The
final assay culture was prepared by dilution of the subculture in single strength folic acid
casei medium to an optical density of 0.01 via spectrophotometer.
After 21 days in culture, harvested lymphoblastoid cells were thawed and excess PBS
was removed, beta-mercaptoethanol was added to buffers, and homogenization buffer
was applied at 3x volume of packed cells. The cells were homogenized to release folates,
centrifuged at 14,000 rpm for 30 minutes at 4°C, and supernatant transferred to new tube.
The extraction buffer was applied at 0.2x volume of supernatant and heated to 100°C for
5 minutes to completely remove folates from their binding protein, then centrifuged at
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12,000 rpm for 5 minutes. Supernatant was distributed into 20 ul aliquots and stored at 80°C or assayed immediately.
Immediately prior to the assay, a master mix of single strength folic acid medium and
working buffer (sodium ascorbate, di H2O, potassium phosphate buffer, filtered through
0.22 um filter) was prepared in a ratio of 150:8 ul. A 96-well microtiter plate was set-up in
low light with duplicate columns of folinic acid standard and blank intrinsic controls ranging
from 0 ul to 60 ul of 2 fmol/ul folinic acid standard solution, with diH2O added to bring well
volume up to 72 ul. 158 ul master mix was added to all wells using a multichannel pipette,
and additional 62 ul single strength folic acid medium was added to sample wells. 10 ul
of cell sample preparation was added to samples wells in triplicate. Finally, 20 ul of
prepared L. Casei culture was added to all wells except blanks to bring total volume to
250 ul/well. The plate was then covered and wrapped in Parafilm and aluminum foil to
prevent light oxidation and incubated at 37°C for 18 hours. The plate was then read at
600nm in BioRad plate reader and standard curve was plotted for comparative analysis.
The results were analyzed using the t-test.
C. Reverse Transcriptase Qualitative PCR Analysis
The mRNA levels of POLβ, UNG2, and AID was quantified via RT-qPCR. Total RNA
was extracted from lymphoblastoid cells cultured in folate adequate and folate deficient
media using the RNeasy Kit (Qiagen, Valencia, CA). cDNA was synthesized from 2 ug
RNA using random hexamer primers and purified using QIAquick PCR purification kit
(Qiagen). Real time RT-PCR was conducted on a LightCycler 480 instrument (Roche,
Indianapolis, IN). PCR reactions contained 2 ug cDNA, 4 nM MgCl2, 0.4 mM each of
sense and antisense primers and 2ml FastStart LightCycler 480 SYBR Green I Master
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(Roche). External standards were prepared by cloning cDNA amplicons into Topoll
vectors, sequenced for confirmation, and used to create 10-log standard curves. All
transcripts were normalized to housekeeping gene B2M for analysis. Data is expressed
as mean ± standard error of the mean (SEM) from at least three independent experiments
and is considered statistically significant at p-value <0.05.
D. Liquid Chromatography with Tandem Mass Spectroscopy
Intracellular deoxyribonucleotide triphosphate levels of folate depleted and folate
adequate lymphoblasts were analyzed by the Pharmacology Core Lab, Karmanos
Cancer Institute. Cell samples were prepared according to the Core Lab standard
procedures and run on a Waters LC-MS/MS system controlled by MassLynx software.
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CHAPTER 4: RESULTS/FIGURES
Intracellular Folate Concentration and Doubling Time
B-lymphoblastoids were cultured at a standard media concentration of 3000 nM
folate and at 12 nM folate to induce deficiency. Our experimental folate level was chosen
based on previous experiments in lymphocytes evaluating proliferation and DNA uracil
incorporation [73, 76]. This was done to allow some inference into the accumulation of
uracil in these cells, and to measure the effects of folate deficiency at a level consistent
with mild deficiency in vivo. Due to reduced proliferation in folate deficient cells, 12 nM
folate is the minimum folate concentration we found feasible for experimental cell volumes
without nucleoside supplementation. Cellular folate deficiency was confirmed by modified
L Casei microbiological folate assay (Figure 4.1). Ten days of 12 nM culture medium was
sufficient to deplete cellular folate levels in lymphoblasts by 93% (p<0.000001). The cells
were depleted by 98% by day 21 (p<0.000001). Cell doubling time at day 3, 6, and 11
was calculated to elucidate the effect of relative folate deficiency on cell proliferation over
time. Unsurprisingly, folate deficient B-lymphoblastoids had significantly decreased
proliferation relative to cells cultured at 3000 nM folate (Figure 4.2). At day 6 in culture,
we observed a trend toward increased doubling time (p>0.05), however this effect was
significantly amplified by time at folate deficiency. By day 11, the proliferation of cells
cultured at 12 nM folate was 20% that of control cells (p<0.05), suggesting significant
number of cells were cell cycle arrested and/or apoptotic.
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Figure 4.1 Relative cell folate concentration
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Figure 4.1: Relative cell folate concentration measured by L. casei
microbiological assay. Lymphoblastoid cells were cultured at 3000 nM folate and 12
nM folate for 21 days. Relative folate concentration was measured by microbiological
assay approximately every 4 days starting at day 10. Experiments were run in triplicate
and results are shown as mean for each assay. Folate concentration and SD fell below
measurable threshold at day 14.
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Figure 4.2 B-lymphoblastoid Doubling Time
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Figure 4.2: Lymphoblastoid Doubling Time. Cellular culture doubling time was
calculated at days 3, 6 and 11 of culture at 3000 nM and 12 nM folate. Live cells were
counted with hemocytometer, recorded per 8ml and reseeded with 106 cells at each
passage.
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Deoxyribonucleotide Triphosphate Levels
Disruption of the cell cycle as a result of folate deficiency has been attributed to
replication inhibition triggered by insufficient deoxyribonucleotide (dRN) levels [77]. We
confirmed this condition in B-lymphoblastoids by assessing the available dNTP pool by
LC-MS/MS. Folate depletion decreased measured dNTP levels among all four dNTPs by
an average of 40%. Individually, dATP decreased 38% in folate depleted vs. folate
adequate cells, 56% in dCTP, 45% in dGTP, and 20% in dTTP. However, as the values
were obtained from a single experiment in limited folate depleted cells, P-values could
not be calculated for these results.

Figure 4.3 dNTP Levels in Folate Deficient B-Lymphoblastoids
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Figure 4.3 Deoxyribonucleotide Triphosphate Levels in Folate Deficient BLymphoblastoids. Cells were cultured for 10 days in folate adequate and folate
depleted conditions. Nucleotides were isolated and quantified by LC-MS/MS.
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Expression of BER Enzymes
Transcriptional regulation of the BER enzyme coding genes UNG2 and POLβ are
known to be influenced by folate deficiency in some cell types. Disruptions in BER
inducibility in B-cells may affect AID-mediated uracil repair. Therefore, we measured the
expression of these enzymes in B-lymphoblastoids. RT-PCR was performed every 3-4
days for three weeks from total RNA extracted from folate deficient and folate adequate
cells. Results are expressed relative to B2m (beta2-microglobulin), which is documented
to be a stable reference of expression in hematopoietic cells [78, 79]. UNG2 mRNA levels
in the folate deficient cells were decreased by 16% after 3 days of culture (p<0.05), these
levels also generally decreased over subsequent days; 6 (p<0.05), 14 (p <0.01), 17
(p<0.01), and 21 (p<0.01), though there was a deviation from this trend at day 10 (Figure
4.3). By day 21 in folate deficiency, there was a 44% decrease in UNG2 expression in Blymphoblastoids. There has been evidence of a lack of POLβ inducibility in folate
deficiency in some cell types [54], and inadequate POLβ in liver tissue is a likely source
of unstable repair intermediates and subsequent DNA strand breaks in folate deficient
cells [55]. This is supported by the POLβ mRNA levels measured by our lab (Figure 4.4).
We found no upregulation of POLβ in the folate deficient B-lymphoblastoids and there is
a trend toward decreased mRNA levels, and a significant reduction observed at days 10
and 17 (p<0.05).
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Figure 4.3 UNG2 Expression in Folate Deficient Lymphoblastoids Relative to B2M
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Figure 4.3: Relative UNG2 Expression in Folate Deficient Lymphoblastoids. RNA
was isolated from folate deficient lymphoblastoids every 3-4 days for 3 weeks. UNG2
gene expression was determined by RT-PCR. Experiments were run in triplicate and
normalized to B2M. Data is presented as mean ±SEM and significance of P<0.05 and
P<0.01 is denoted by *, and ** respectively.
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Figure 4.4 POLβ Expression in Folate Deficient Lymphoblastoids Relative to B2M
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Figure 4.4: POLβ Expression in Folate Deficient Lymphoblastoids. RNA was
isolated from folate deficient lymphoblastoids every 3-4 days for 3 weeks. POLβ gene
expression was determined by RT-PCR. Experiments were run in triplicate and
normalized to B2M. Data is presented as mean ±SEM and * denotes significance at
P<0.05.
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AID Expression
APOBEC-family cytosine deaminase AID interacts functionally with UNG2 in
adaptive immunity and may also introduce uracil into non-target genes [80, 81]. The
expression of AID in folate deficient B-cells, as well as the interaction between AID and
BER transcript regulation in this condition has not been previously reported. In Blymphoblastoids cultured in 12 nM folate, we found that AID mRNA levels were decreased
by 34% and 30% at days 3 (p<0.0005) and 6 (p<0.001) respectively, compared to folate
adequate cells. Interestingly, at day 10 of folate deficiency AID expression increased by
25% (p<0.001) and remained upregulated at days 17 (p<0.005) and 21 (p<0.01). Taken
together, these findings suggest an inverse relationship between UNG2 and AID gene
expression in folate depleted B-lymphoblastoids.
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Figure 4.5 AID Expression in Folate Deficient Lymphoblastoids Relative to B2M

Figure 4.5: AID Expression in Folate Deficient Lymphoblastoids. RNA was isolated
from folate deficient lymphoblastoids every 3-4 days for 3 weeks. AID gene expression
was determined by RT-PCR. Experiments were run in triplicate and normalized to B2M.
Data is presented as mean ±SEM and significance of P<0.01 and P<0.001 is denoted
by * and ** respectively.
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CHAPTER 5: DISCUSSION
Folate deficiency has been tied to reduced dNPT availability, stalled replication,
BER dysregulation and DNA strand breaks [6, 54, 61, 82]. In the context of AID activity in
activated B-cells, a disruption of BER may have significant implications for the processing
of genomic uracil. However, we have found that the consequences of DNA repair
imbalance in folate deficiency is not consistent among tissue types. Due to a reported
increase in uracil accumulation in lymphocytes, we expected that BER inducibility was
decreased in these cell types. In support of our hypothesis, we observe a significant stepwise decrease in UNG2 that follows the length of time in folate deficient media. In addition,
upregulation of POLβ is blocked by folate deficiency, further limiting the ability of AIDinduced uracils to be repaired in these cells. Thus, we establish an inverse relationship
between AID expression and BER inducibility in folate deficient hematopoietic cells,
increasing the risk for DNA strand breaks and oncogenic mutations resulting from
unrepaired AID-induced genomic uracil.
Proliferation and dNTP Availability
We observed a reduction of dNTP levels in B-lymphobastoids which confirms
folate depletion in these cells and provides further evidence that the availability of all four
dNTPs are reduced by folate depletion in vitro (Figure 4.3). Phenotypic depletion of
dNTPs due to a reduction in dRN precursors results in a global inhibition of DNA
replication and fork stalling [74, 77]. As expected, proliferation in these cells was
decreased in parallel with duration in folate deficiency (Figure 4.2), indicating significant
growth arrest within 11 days in 12 nM folate media. Generally, cell cycle arrest is a marker
of induction of cell cycle checkpoints, DNA damage and initiation of repair mechanisms,
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though we cannot distinguish the stage of arrest in these cells without cell cycle analysis.
When flow cytometry was completed in lymphocytes grown for 10 days at 12 nM folate,
Mashiyama et. al. reported that approximately 45% of the cells were arrested in S phase,
and another 45% in G0/1 [73]. This provides good evidence that lymphocytes grown at
this level of folate are blocked in S-phase, likely in association with reduced dNTP levels.
Additionally, prior research by Courtemanche et. al. indicates that there is a dosedependent induction of apoptosis in folate deficiency, with significant cell death only
demonstrated in cells cultured in 6 nM folate and below [82], well below our experimental
cells.
There is evidence that the cell proliferation rate directly impacts the uracil content
of DNA in folate deficient cells [83]. In the same publication, Mashiyama et. al. found that
when proliferation was drastically reduced in lymphocytes by culturing in 0 nM folate
medium for 10 days, uracil in DNA measured by GC-MS was not significantly different
from the uracil content in cells at standard folate concentrations. However, when the
media folate concentration was increased to 12 nM, DNA uracil content increased 6.5fold [73]. This suggests that moderately folate deficient lymphocytes, such as those
cultured at 12 nM folate have more uracil content than those in severe folate depletion.
Whether this is a consequence of increased dUMP misincorporation, cytosine deaminase
activity, decreased repair capacity, or a combination of all three remains unknown.
Nonetheless, S phase block in folate deficiency may serve to preserve dNTPs for DNA
damage repair, or alternatively prevent DNA synthesis under suboptimal conditions.
Since we know that the proliferation rate is quickly restored in arrested cells once folate
deficient cells are provided with folate or dNTP precursors [73], the severity of folate
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deficiency may be an important non-dose dependent modifier of DNA damage. As cells
in moderate folate deficiency favor arrest over the apoptosis observed in severe folate
depletion [73, 76], repair of uracil accumulation in moderate deficiency may be sensitive
to a lag in repair capacity once folate, and consequently replication is restored. This would
imply that frequent fluctuations in folate availability may be detrimental vis-à-vis
insufficient DNA repair of genomic uracil, though this effect has yet to be confirmed.
Tissue Specific BER Response
Folate deficiency disrupts DNA repair through imbalance in the BER pathway [54,
55]. This has been demonstrated by a normally induced UNG2 response to DNA damage,
without a corresponding upregulation of POLβ in murine liver tissue and BNL.C2 cells
[54]. Correspondingly, there is no accumulation of uracil in these cells types due to the
action of UNG2 [unpublished results] however, there is an increase in mutagenic repair
intermediates, specifically 3’-OH containing lesions [55]. In contrast, we have also found
that damage-induced upregulation of UNG2 is inhibited in folate deficient MEFs, and that
uracil does accumulate in the genome of these cells [unpublished results]. Additionally,
when Ung-null MEFs were depleted of folate there was a 3-fold increase in detected DNA
uracil levels [unpublished results], establishing tissue specific UNG2 regulation as a
primary factor in determining the fate of uracil in DNA.
Here we show that UNG expression is decreased in folate deficient Blymphoblastoids, and that the expression decreases over time in this condition. This is
consistent with the evidence that DNA uracil does in fact accumulate in folate deficient
conditions in lymphocytes [73]. We also find no upregulation of POLβ in these cells,
suggesting a complete loss of the BER inducibility response.
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There is precedent for tissue specificity in the BER pathway. Karahalil et. al. found
that UNG activity differed drastically among solid tissues with heart tissues having the
highest activity of the tissues measured, and muscle the lowest, though no hematopoietic
cells were measured in this study [84]. It is reasonable to speculate that highly proliferative
progenitor cells such as MEFs and B-lymphoblastoids place preservation of the genome
at a higher priority than fully differentiated cells, and thus limit potentially mutagenic repair
activities to a greater extent. However, in terms of uracil processing it remains unclear
which tissue specific phenotype of folate deficiency is favorable. Continued upregulation
of UNG2 without the corresponding POLβ response results in an accumulation of repair
intermediates, as seen in liver tissue, is almost certainly detrimental, and likely
responsible for the increase in DNA strand breaks and chromosomal aberrations
characteristic of folate deficiency in the literature [37, 55, 61]. However, depending on the
source of the uracil, genomic uracil that escapes repair prior to replication may result in
an oncogenic somatic mutation. Misincorporation of uracil, as occurs as a result of folate
deficiency-induced rise in dUMP:dTMP ratio, results in a U:A mismatch that is not
miscoding, though could result in mutations at abasic sites or during gap-filling in BER
[55]. However, deamination of cytosine in DNA results in a C to T transition mutation since
the copying of uracil during replication will invariably result in the generation of a U:A pair,
and eventually at T:A pair, in the place of the original C:G pair (Figure 1.7). This type of
transition mutation is the most common mutation found in human cancer [68, 81], and
may be more likely to occur in cells that phenotypically accumulate uracil in response to
folate deficiency, such as lymphocytes.
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Imbalance of AID and UNG2 Expression in Folate Deficiency
AID converts cytosine to uracil in Ig genes to create antibody diversity through
SHM and CSR. AID is also strongly connected to cancer in animals, and many human B
cell lymphomas constitutively express AID [72, 75, 81]. In both the error prone AIDinduced uracil repair pathway in Ig genes, and the non-error prone BER repair of
deaminated cytosine genome-wide, UNG2 is the primary DNA glycosylate responsible
for base excision. Shalhout et. al. has established that UNG2 gene expression parallels
AID expression following B-cell stimulation in WT mouse splenocytes, and that the
upregulation of UNG2 was 2.5-fold higher in WT cells than in AID -/- cells [75]. This finding
confirms a regulatory balance between UNG2 and AID. Folate deficiency is known to
modulate UNG2 expression, although this effect is tissue-dependent, as we have
established. Lymphocytes accumulate uracil in their DNA when folate is deficient [73],
possibly due to inhibition of BER inducibility. Since AID is known to actively generate DNA
uracils in B-cells, we measured the relative expression of UNG2 and AID in our
experimental cells (Figures 4.3, 4.5). Here, in contrast to the direct correlation between
UNG2 and AID in WT cells, we find an inverse association between the relative
expression of UNG2 and AID after 10 days of folate deficiency in B-lymphoblastoids.
The balance between uracil creation by AID-mediated cytosine deamination and
uracil elimination by BER or MMR mechanisms is tightly controlled in normal stimulated
B-lymphocytes. The resulting homeostasis maintains low genomic uracil content in typical
conditions. This has been confirmed in stimulated WT B-cells, since uracil only
accumulates when UNG2 is inactivated [75]. This is true throughout the whole genome
and is not specific to the Ig loci [75]. It is known that AID acts on non-Ig target genes,
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possibly to a large extent [80]. This off-target action resulting in deaminated cytosines is
repaired by short-patch BER, with the excision primarily completed by UNG2. In folate
deficiency we find that UNG2 is downregulated, presumably disturbing the balance of
uracil creation and excision. The downregulation of AID that we observed in the first six
days of folate deficiency may be protective in light of the concurrent downregulation of
UNG2. However, by day ten, UNG2 continues to decrease while AID is upregulated.
Previous work from our lab has demonstrated a tight correlation between levels of UDG
protein and UDG activity [55], suggesting that the inverse relationship between UNG2
and AID in the folate deficient state may result in significant uracil formation and
accumulation in these cells. The parallel kinetics of UNG2 gene expression and nuclear
uracil excision activity was also confirmed by Shalhout et. al [75]. As discussed,
deamination of cytosine by AID will result in a U:G mismatch, and may result in a C to T
transition mutation if left unprocessed by UNG2 prior to replication (Figure 1.7).
Transitions of this kind are by far the most prevalent mutations found in human cancer
[68].
A recent study by Alvarez-Prado et. al using machine learning of high-through-put
sequencing of >1500 genomic regions from germinal center B-cells has found that 2.3%
of the genome or ~500 genes are likely targets of AID mutations, and that both the BER
and MMR pathways contribute to reducing mutations at off target AID sites [80].
Additionally, chromosomal translocations resulting from faulty repair of uracil lesions are
a frequent source of lymphomagenesis. These translocations frequently occur between
proto-oncogenes such as Bcl-2 (B-cell lymphoma-2) and c-Myc and the IG locus, as well
as at off-target sites [80, 85]. Though it is outside the scope of this paper, inducibility of
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error prone BER at the Ig locus may also be dysregulated by folate deficiency during SHM
and CSR due to their reliance on UNG2, resulting in unknown effects from AID action. In
addition, off-target deamination by other ABOBEC family enzymes active in the innate
immune system provide additional uracil substrate for UNG2-initiated BER. These lesions
result in C to T transition mutations if left unprocessed in a manner similar to AID, although
the extent to which non-AID APOBEC enzymes introduce uracils into off target loci is
undetermined.
So far, epidemiological evidence linking folate deficiency in humans to risk of Bcell lymphomas has been equivocal, and very few cohort studies have been completed
on this topic [86]. However, in a population-based study of 1,304 Connecticut women,
Koutros et. al. found lower risks of diffuse large B-cell lymphoma (OR = 0.54) and NonHodgkins’s lymphoma overall, and marginal zone lymphoma (OR = 0.23) in the highest
vs. lowest quartile of folate intake reported by food frequency questionnaires [87].
Additionally, while rates of overt folate deficiency in the US are low, the level of depletion
modeled in our experiment is consistent with only moderate sub-clinical folate deficiency
in vivo, which undoubtedly comprises a larger share of the population. However, it is
important to keep in mind that incongruities in direct comparison may exist due to
differences in the uptake of specific folate forms and known genetic SNPs affecting folate
metabolism.
Interestingly, in both murine and human lymphoma cell lines, Shalhout et. al.
observed high rates of accumulated uracil at AID preferred sequences (AID hotspots)
despite UNG2 and AID activity similar to non-cancer cell lines [75]. They propose that
during maturation some B-cells may lose coordination between uracil creation and
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elimination, creating a “DNA repair crisis.” However, if the excisional activity eventually
catches up with uracil lesions to stabilize the cell, a new steady state condition may occur
at a uracil level that is much higher than typical cells.
Building upon these studies by Shalhout et. al. on UNG2 and AID, here we
introduce a nutritional modifier that directly impacts uracil excision coordination with AID.
Further research is needed to explore the relationship between UNG2 and AID in folate
deficiency, including downstream effects of uracil accumulation in AID expressing B-cells.
We also observed a significant reduction in intracellular folate concentration, proliferation
and dNTP levels in B-cells at moderately depleted folate media. Given the complex
association between folate status and carcinogenesis, it is possible that modest
fluctuations in folate availability confer yet unknown influence on the cell cycle and DNA
repair/AID interaction. In conclusion, these findings provide preliminary evidence of a
nutritionally-induced mechanism by which the AID/BER functional interaction may
become destabilized and increase risk for the AID hotspot oncogenic mutations described
in the literature [72, 80, 81]. Specifically, dysregulation between AID and UNG2 in Blymphoblastoids increases the risk transition mutations resulting from unrepaired AIDinduced genomic uracil.
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CHAPTER 6: CONCLUSION
B-lymphoblasts deprived of folate at physiologic levels have a corresponding
decrease intracellular folate and dNTP levels, and 80% decrease in proliferation by day
10 in vitro. The nuclear uracil DNA glycosylase UNG2 is downregulated in this condition,
limiting DNA repair capacity. Regulation of UNG2 in folate deficiency is likely a tissuespecific response in lymphocytes and other normally highly proliferative cells, possibly in
an attempt to limit mutagenic repair intermediates resulting from insufficient POLβ activity
in BER however, at the expense of increased DNA uracil content. Expression of AID in
cultured EBV-transformed B-lymphoblasts has been documented to correlate well with
genomic cytosine deaminase activity [75]. In normal activated human lymphocytes, UNG2
and AID are functionally linked, and their expression and activity are highly synchronized.
When exposed to folate deficient media AID mRNA is decreased initially, but by day 10
levels are upregulated. These modulations are significant, though weak. This response
is inversely correlated with both UNG2 expression and cell proliferation. It remains
unknown whether this discoordination between UNG2 and AID in folate deficiency results
in an accumulation of genomic uracil in these slowly proliferating cells, or if this imbalance
occurs in vivo, specifically at AID mutational hotspot sequences. Additionally, if AID
activity continues during cell cycle arrest, as is suggested here, supplementation of folate
or nucleosides to rescue cells from S phase block, may have yet to be determined
consequences associated with a lag in the repair of uracil lesions in newly replicated cells.
Given growing evidence of off-target AID action playing a role in oncogenic
transformation, the role of folate deficiency in the dysregulation between BER and AID
warrants additional investigation.
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ABSTRACT
IMBALANCE OF URACIL DNA GLYCOSYLASE AND ACTIVATION-INDUCED
CYTIDINE DEAMINASE EXPRESSION IN FOLATE DEPLETED HUMAN
LYMPHOBLASTOIDS
by
ELIZABETH ZANLEY
May 2019
Advisor: Dr. Diane Cress
Major: Nutrition and Food Science
Degree: Master of Science
Background: The DNA base excision repair (BER) pathway is responsible for
processing of genomic uracil lesions however, in some tissue types the excisional and
gap-filling steps performed by UNG2 and POLβ, respectively, are impaired by folate
deficiency in human and murine models in vitro. Genomic uracil damage can be acquired
by inadequate conversion of uracil to thymine nucleotide precursors resulting from
insufficient folate cofactors, or through activation induced cytosine deaminase (AID)
activity during antibody diversification in B-cells in the context of adaptive immunity. The
immunoglobulin (Ig) diversification methods in B-cells depend on the coordinated
interaction between AID and UNG2, and as such, their analogous transcriptional
regulation has been established. However, AID-induced uracil lesions at non-Ig loci have
been found to be associated with lymphomagenesis, suggesting a functional BER deficit.
Therefore, the objective of this research is to establish the tissue specific effect of folate
deficiency on BER enzymes in B-lymphoblastoids, and to examine the functional
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coordination between AID expression and BER inducibility during moderate folate
deficiency in B-cells in vitro. Methods: Human B-lymphoblastoid cells were cultured in
12nM and standard folate media concentration for 21 days. Intracellular folate
concentration measured by microbiological assay, doubling time, and genetic expression
of UNG, POLβ, and AID analyzed by RT-qPCR was completed with culture samples taken
every 3-4 days. Results: Within 10 days in moderate folate deficient media, intracellular
folate concentration was decreased by 93%, and cell proliferation was reduced by 80%.
Expression of UNG was significantly downregulated by 16% at day 3 of folate deficiency,
and by 44% at day 21. AID mRNA levels were significantly increased by 25% by day 10,
demonstrating an inverse relationship between UNG2 and AID gene expression.
Conclusion: Tissue specific downregulation of BER in folate deficient B-lymphoblastoids
results in a functional imbalance between AID and uracil repair capacity, possibly
increasing the risk of oncogenic transition mutations resulting from unrepaired AIDinduced genomic uracil.
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